Naploy Corp.

What they do

Naploy Corp. runs the Naploy App, a health news blog covering nutrition, fitness, diseases and health policy, available on the Apple App Store and via its web application, with Android download via a direct APK file. The app's main features are a Symptom Diagnostic tool that uses AI to return about five possible conditions, and a Clinic Search feature where users pay a fee to request help finding medical institutions. The company states it has no employees, only two officers and directors, and its executive office is in Abuja, Nigeria.

Revenue drivers

• Clinic Search service — Clients contact the company and pay a fee for a request to search clinics and medical services suited to their needs; staff then follow up by phone, email or messenger with information on institutions, licenses and doctors.
• Contextual advertising for medical institutions — The Naploy app's news blog offers paid banner ads (static or animated images placed in high-visibility areas) and pop-up ads aimed at generating awareness and leads for medical institutions.
• App-based health information platform — The core asset is the free Naploy App news blog and Symptom Diagnostic tool, which the company describes as not requiring regulatory approval in the U.S., Nigeria or elsewhere because it provides information rather than direct medical advice.

Recent performance

Annual revenue rose from $0.00 in 2024 to $7,950 in 2025, while net loss widened slightly from $20,301 to $20,714 and diluted EPS stayed at -$0.01. Operating cash flow was -$17,001 in 2024 and -$21,165 in 2025. Recent quarterly revenue has grown sequentially: $3,577 for the quarter ended 2025-07-31, $3,633 for 2025-10-31, $4,500 for 2026-01-31, and $4,996 for 2026-04-30. At 2026-04-30 total assets were $55,591, cash and equivalents were $15,716, and shareholder equity was negative $19,912.

Strategy

Management's stated focus is launching and building out the Naploy health news blog and app, with the Symptom Diagnostic AI tool to be refined and improved over the app's lifetime. Distribution currently includes the Apple App Store, the company's web application at naploy.com, and a direct APK download for Android. Monetization plans center on the paid Clinic Search request service and contextual advertising (banner and pop-up ads) sold to medical institutions on the app's news blog. The company reports having developed a full business plan and describes its market rationale around post-COVID demand for mobile healthcare information.

Risks

• Minimal revenue and recurring losses — Revenue was only $7,950 in 2025 against a $20,714 net loss, and the company states it has no sufficient revenue and has incurred losses since inception.
• Negative shareholder equity and cash burn — Shareholder equity was -$19,912 and cash was $15,716 at 2026-04-30, while operating cash flow was -$21,165 in 2025.
• No employees, two-person management — The company has no employees and depends entirely on officers and directors Mr. Frederick Sidney Reinhard Arnold and Mr. Rafael Angel Ulloa Bonilla.
• Information-only positioning limits the product — The Symptom Diagnostic tool is stated to be informational only, not medical advice or a definite diagnostic tool, and the company says it does not require regulatory approval on that basis.

Outlook

The filings describe ongoing work to refine and improve the AI Symptom Diagnostic tool over the app's lifetime. Management presents the business plan as developed and the app as launched across the App Store, web application, and Android APK channels, with paid Clinic Search and advertising as the intended revenue sources. No specific financial guidance or forecast figures are provided in the supplied excerpts.